The Unsatisfied Need for Obviating Erectile Dysfunction
There is an unsatisfied need for obviating Erectile Dysfunction that current drugs cannot meet.
AE Medical is a Massachusetts biotech corporation, and the owner of intellectual property on devices and methods enabling AE technology to enter vast erectile dysfunction markets now dominated by Erectile Dysfunction (ED) drugs such as Viagra.
Last year Viagra gained $2 billion in sales for Pfizer, nearly 60 percent of which was in the United States. In addition, all new ED drugs on the market work by blocking an enzyme called PDE-5, which affects penile blood flow, but not without potentially harmful side-effects.
A large business opportunity is created by the need and demand of the estimated 30 million men over 40 years of age who cannot achieve an erection with Viagra or any other ED drug treatment.
Analysts at Merrill Lynch believe there is room for new entrant competition for erectile dysfunction, since their estimate is that more than 28 percent of male patients who have tried Viagra and other internal, invasive ED drugs with side-effects, and after extended trials are left unfulfilled and frustrated because they simply cannot achieve an adequate erection for sexual intercourse.
The AE proprietary external, non-invasive technology without side-effects, proven to be effective for men who cannot benefit from ED drugs, and a much lower cost ED device solution and method. The present refined and tested, easier to use AE device for non-prescription, over the counter sales, has been proven reliable and capable of consistent, repeatable erection enhancement and performance for all men.
The main AE business strategy is to produce and market this safe, full-erection capability directly to the consumer through advertising, Internet web sites, mail order, retail stores, and pharmacies. Only licensed medical physicians can prescribe Viagra, and medical insurance for all males generally limits payment for only about four ED drug pills per month at a cost of about $500 per year.
Since the AE device is reusable and costs significantly less than Viagra, there is a larger ready market for AE Medical, with the only practical, effective erectile device for all men to enhance their performance.
The AE device and method was originally designed and developed with a Urologist under a CDA for an older patient with Impotence who was operated on for Prostate Cancer and is also a Type II diabetic. AE conducted further research with a Cardiologist in Internal Medicine, who wants to have an ED alternative to replace the use of Viagra and related ED drugs with their side effects and the attendant cardiovascular risks.
AE is reviewing the design with the FDA for final release to production and sales through Physicians and Medicare approved outlets.
David Estabrooks has a (CDA) Confidential Disclosure Agreement with members of the Joslin Diabetic Clinic for their interest in the AE external penile device for erection capability in Diabetic men, where more than 50% have unsolved erectile dysfunction. AE Medical is planning to obtain FDA approval and Medicare authorization for 80% reimbursement in order to satisfy the prescription ED device demand by physicians.
AE Erectile Devices are designed over counter, non-prescription and consumer sales. But also to meet external ED device FDA guidelines and materials standards for Medicare and medical prescription by physicians, the proprietary AE device and method is the only solution capable of effectively creating erections, and at the lowest possible cost.
Without a strict requirement for a prescription by a physician, AE can easily thru conventional sales outlets, enter into the rapidly growing Viagra dominated marketplace for all male age groups.
Since Viagra is only prescribed by licensed medical physicians, medical insurance for males generally limits payment for only about four Viagra pills per month at a cost of about $50, AE Medical will have a significant low price advantage with much less restriction of use by all males.
Medicare has a patient reimbursement program with a physician's prescription for any FDA approved external, non-invasive ED devices and methods without side-effects. And, in the case Medicare reimbursement with a physcian, AE will have a very large market.
At much lower consumer cost, simple, reliable AE products will capture large sales revenues with adequate profit margins for AE Medical investors. The AE business strategy is to become the most popular penile erection treatment for erectile dysfunction.
The new AE products will succeed, where other current ED devices for obviating erectile dysfunction have failed in achieving substantial revenue growth in supplanting Viagra and other ED drugs. AE will follow this focused, logical progression to make its high quality, low cost, safe effective product, the preferred ED solution, the "must have" AE erection device and method.
With the potential for large customer interest and demand, U.S. Patent Applications are filed to protect the AE Apparatus and Method for Obviating Erectile Dysfunction. There are no competitive products currently on the market, and no evidence of prior art, or any patent like the proprietary AE Technology.
It is anticipated that AE Erectile Devices due to their simplicity and ease of use will enjoy a high success rate with increasing consumer and medical acceptance.
AE will change the face of the erectile treatment industry over the next few years. It is planned that the AE venture development will be financed entirely with individual and angel investment in AE Medical Common Stock.
Additional funding will be derived with hospitals such as the Joslin Diabetic Clinic and other institutions becoming involved in licensing and sales participation.
It is estimated that the first stage of product development, manufacture, and sales does not require more than $350,000 to reach profitability. For investor information and a CDA to learn more about this revolutionary AE Technology,
AE Medical is a Massachusetts biotech corporation, and the owner of intellectual property on devices and methods enabling AE technology to enter vast erectile dysfunction markets now dominated by Erectile Dysfunction (ED) drugs such as Viagra.
Last year Viagra gained $2 billion in sales for Pfizer, nearly 60 percent of which was in the United States. In addition, all new ED drugs on the market work by blocking an enzyme called PDE-5, which affects penile blood flow, but not without potentially harmful side-effects.
A large business opportunity is created by the need and demand of the estimated 30 million men over 40 years of age who cannot achieve an erection with Viagra or any other ED drug treatment.
Analysts at Merrill Lynch believe there is room for new entrant competition for erectile dysfunction, since their estimate is that more than 28 percent of male patients who have tried Viagra and other internal, invasive ED drugs with side-effects, and after extended trials are left unfulfilled and frustrated because they simply cannot achieve an adequate erection for sexual intercourse.
The AE proprietary external, non-invasive technology without side-effects, proven to be effective for men who cannot benefit from ED drugs, and a much lower cost ED device solution and method. The present refined and tested, easier to use AE device for non-prescription, over the counter sales, has been proven reliable and capable of consistent, repeatable erection enhancement and performance for all men.
The main AE business strategy is to produce and market this safe, full-erection capability directly to the consumer through advertising, Internet web sites, mail order, retail stores, and pharmacies. Only licensed medical physicians can prescribe Viagra, and medical insurance for all males generally limits payment for only about four ED drug pills per month at a cost of about $500 per year.
Since the AE device is reusable and costs significantly less than Viagra, there is a larger ready market for AE Medical, with the only practical, effective erectile device for all men to enhance their performance.
The AE device and method was originally designed and developed with a Urologist under a CDA for an older patient with Impotence who was operated on for Prostate Cancer and is also a Type II diabetic. AE conducted further research with a Cardiologist in Internal Medicine, who wants to have an ED alternative to replace the use of Viagra and related ED drugs with their side effects and the attendant cardiovascular risks.
AE is reviewing the design with the FDA for final release to production and sales through Physicians and Medicare approved outlets.
David Estabrooks has a (CDA) Confidential Disclosure Agreement with members of the Joslin Diabetic Clinic for their interest in the AE external penile device for erection capability in Diabetic men, where more than 50% have unsolved erectile dysfunction. AE Medical is planning to obtain FDA approval and Medicare authorization for 80% reimbursement in order to satisfy the prescription ED device demand by physicians.
AE Erectile Devices are designed over counter, non-prescription and consumer sales. But also to meet external ED device FDA guidelines and materials standards for Medicare and medical prescription by physicians, the proprietary AE device and method is the only solution capable of effectively creating erections, and at the lowest possible cost.
Without a strict requirement for a prescription by a physician, AE can easily thru conventional sales outlets, enter into the rapidly growing Viagra dominated marketplace for all male age groups.
Since Viagra is only prescribed by licensed medical physicians, medical insurance for males generally limits payment for only about four Viagra pills per month at a cost of about $50, AE Medical will have a significant low price advantage with much less restriction of use by all males.
Medicare has a patient reimbursement program with a physician's prescription for any FDA approved external, non-invasive ED devices and methods without side-effects. And, in the case Medicare reimbursement with a physcian, AE will have a very large market.
At much lower consumer cost, simple, reliable AE products will capture large sales revenues with adequate profit margins for AE Medical investors. The AE business strategy is to become the most popular penile erection treatment for erectile dysfunction.
The new AE products will succeed, where other current ED devices for obviating erectile dysfunction have failed in achieving substantial revenue growth in supplanting Viagra and other ED drugs. AE will follow this focused, logical progression to make its high quality, low cost, safe effective product, the preferred ED solution, the "must have" AE erection device and method.
With the potential for large customer interest and demand, U.S. Patent Applications are filed to protect the AE Apparatus and Method for Obviating Erectile Dysfunction. There are no competitive products currently on the market, and no evidence of prior art, or any patent like the proprietary AE Technology.
It is anticipated that AE Erectile Devices due to their simplicity and ease of use will enjoy a high success rate with increasing consumer and medical acceptance.
AE will change the face of the erectile treatment industry over the next few years. It is planned that the AE venture development will be financed entirely with individual and angel investment in AE Medical Common Stock.
Additional funding will be derived with hospitals such as the Joslin Diabetic Clinic and other institutions becoming involved in licensing and sales participation.
It is estimated that the first stage of product development, manufacture, and sales does not require more than $350,000 to reach profitability. For investor information and a CDA to learn more about this revolutionary AE Technology,